SGMO Sangamo Therapeutics Inc.

14.45
-0.30  -2%
Previous Close 14.75
Open 14.75
Price To book 6.23
Market Cap 1208176609
Shares 83,610,838
Volume 1,501,841
Short Ratio 4.90
Av. Daily Volume 1,619,900

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171075604
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018536
  3. 8-K - Current report 171017983
  4. 8-K - Current report 17938678
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17925344

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiated early 2017 with data due late 2017 or early 2018.
SB-318
MPS Type 1
Phase 1/2 data due late 2017 or early 2018.
SB-FIX
Hemophilia B
Phase 1/2 trial initiated early 2017 with data due late 2017 or early 2018.
SB-913
MPS Type 2
Data presented Dec 2015
SB-728-1401
HIV/AIDS
Data presented Dec 2015
SB-728-1101
HIV/AIDS

Latest News

  1. The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
  2. Why These 4 Biotech Stocks May Not Lose Momentum Soon
  3. Today's Research Reports on Stocks to Watch: Sangamo Therapuetics and Nutanix
  4. 3 Biotech Stocks That Skyrocketed This Week
  5. Sangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit
  6. Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences
  7. Why Abeona Therapeutics Inc. (and Maybe Sangamo Therapeutics, Inc.) Jumped Higher Today
  8. Sangamo Therapeutics Initiates Dosing in Hemophilia A Study
  9. Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A
  10. This Stock Could Be the Tesla of Healthcare
  11. These Stocks Have Tripled This Year
  12. Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : August 17, 2017
  13. This Technology Could Make You Rich -- and Change the World As We Know It
  14. Edited Transcript of SGMO earnings conference call or presentation 9-Aug-17 9:00pm GMT
  15. Sangamo Therapeutics Announces Presentation At The 2017 Wedbush PacGrow Healthcare Conference
  16. Sangamo reports 2Q loss
  17. Sangamo Therapeutics Reports Second Quarter 2017 Financial Results
  18. Investor Network: Sangamo Therapeutics, Inc. to Host Earnings Call
  19. Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : August 3, 2017
  20. Sangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast

SEC Filings

  1. CT ORDER - Confidential treatment order 171075604
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018536
  3. 8-K - Current report 171017983
  4. 8-K - Current report 17938678
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17925344
  6. 8-K - Current report 17923199
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17920900
  8. EFFECT - Notice of Effectiveness 17904253
  9. CORRESP [Cover] - Correspondence
  10. CORRESP [Cover] - Correspondence